{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T23:29:26Z","timestamp":1790638166627,"version":"4.1.0"},"reference-count":201,"publisher":"MDPI AG","issue":"23","license":[{"start":{"date-parts":[[2022,11,29]],"date-time":"2022-11-29T00:00:00Z","timestamp":1669680000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"National Center for Advancing Translational Sciences (NCATS) award","award":["KL2 TR001435"],"award-info":[{"award-number":["KL2 TR001435"]}]},{"name":"National Center for Advancing Translational Sciences (NCATS) award","award":["20CDA35310099"],"award-info":[{"award-number":["20CDA35310099"]}]},{"name":"AHA Career Development Award","award":["KL2 TR001435"],"award-info":[{"award-number":["KL2 TR001435"]}]},{"name":"AHA Career Development Award","award":["20CDA35310099"],"award-info":[{"award-number":["20CDA35310099"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>Pulmonary arterial hypertension (PAH) is a progressive disease characterized by increased pulmonary vascular resistance (PVR), causing right ventricular hypertrophy and ultimately death from right heart failure. Heterozygous mutations in the bone morphogenetic protein receptor type 2 (BMPR2) are linked to approximately 80% of hereditary, and 20% of idiopathic PAH cases, respectively. While patients carrying a BMPR2 gene mutation are more prone to develop PAH than non-carriers, only 20% will develop the disease, whereas the majority will remain asymptomatic. PAH is characterized by extreme vascular remodeling that causes pulmonary arterial endothelial cell (PAEC) dysfunction, impaired apoptosis, and uncontrolled proliferation of the pulmonary arterial smooth muscle cells (PASMCs). To date, progress in understanding the pathophysiology of PAH has been hampered by limited access to human tissue samples and inadequacy of animal models to accurately mimic the pathogenesis of human disease. Along with the advent of induced pluripotent stem cell (iPSC) technology, there has been an increasing interest in using this tool to develop patient-specific cellular models that precisely replicate the pathogenesis of PAH. In this review, we summarize the currently available approaches in iPSC-based PAH disease modeling and explore how this technology could be harnessed for drug discovery and to widen our understanding of the pathophysiology of PAH.<\/jats:p>","DOI":"10.3390\/cells11233823","type":"journal-article","created":{"date-parts":[[2022,11,29]],"date-time":"2022-11-29T01:42:02Z","timestamp":1669686122000},"page":"3823","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["The Role of Bone Morphogenetic Protein Receptor Type 2 (BMPR2) and the Prospects of Utilizing Induced Pluripotent Stem Cells (iPSCs) in Pulmonary Arterial Hypertension Disease Modeling"],"prefix":"10.3390","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2483-7660","authenticated-orcid":false,"given":"Anichavezhi","family":"Devendran","sequence":"first","affiliation":[{"name":"Cardiovascular Research Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA"},{"name":"Black Family Stem Cell Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumanta","family":"Kar","sequence":"additional","affiliation":[{"name":"Cardiovascular Research Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rasheed","family":"Bailey","sequence":"additional","affiliation":[{"name":"Cardiovascular Research Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6601-3267","authenticated-orcid":false,"given":"Maria Giovanna","family":"Trivieri","sequence":"additional","affiliation":[{"name":"Cardiovascular Research Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA"},{"name":"Department of Medicine, Cardiology Unit, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,11,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"4306","DOI":"10.1172\/JCI60658","article-title":"Molecular pathogenesis of pulmonary arterial hypertension","volume":"122","author":"Rabinovitch","year":"2012","journal-title":"J. Clin. Investig."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1161\/CIRCRESAHA.115.301146","article-title":"Pulmonary arterial hypertension: The clinical syndrome","volume":"115","author":"Lai","year":"2014","journal-title":"Circ. Res."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1093\/eurheartj\/ehv317","article-title":"2015 ESC\/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT)","volume":"37","author":"Galie","year":"2016","journal-title":"Eur. Heart J."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1161\/CIRCULATIONAHA.119.040292","article-title":"The New World Symposium on Pulmonary Hypertension Guidelines: Should Twenty-One Be the New Twenty-Five?","volume":"140","author":"Ruopp","year":"2019","journal-title":"Circulation"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.jacc.2013.10.029","article-title":"Updated clinical classification of pulmonary hypertension","volume":"62","author":"Simonneau","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1183\/09031936.02.02702002","article-title":"Genetics of pulmonary hypertension: From bench to bedside","volume":"20","author":"Humbert","year":"2002","journal-title":"Eur. Respir. J."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.jacc.2009.04.012","article-title":"Updated clinical classification of pulmonary hypertension","volume":"54","author":"Simonneau","year":"2009","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/978-1-60761-500-2_16","article-title":"Role of bone morphogenetic protein receptors in the development of pulmonary arterial hypertension","volume":"661","author":"Morrell","year":"2010","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"West, J., Cogan, J., Geraci, M., Robinson, L., Newman, J., Phillips, J.A., Lane, K., Meyrick, B., and Loyd, J. (2008). Gene expression in BMPR2 mutation carriers with and without evidence of pulmonary arterial hypertension suggests pathways relevant to disease penetrance. BMC Med. Genom., 1.","DOI":"10.1186\/1755-8794-1-45"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jacc.2013.10.035","article-title":"Genetics and genomics of pulmonary arterial hypertension","volume":"62","author":"Soubrier","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"814222","DOI":"10.3389\/fmed.2021.814222","article-title":"Therapeutic Approaches for Treating Pulmonary Arterial Hypertension by Correcting Imbalanced TGF-beta Superfamily Signaling","volume":"8","author":"Andre","year":"2021","journal-title":"Front. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/1750-1172-8-97","article-title":"Pulmonary arterial hypertension","volume":"8","author":"Montani","year":"2013","journal-title":"Orphanet. J. Rare Dis."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1183\/09031936.03.00054103","article-title":"Novel therapeutic perspectives in pulmonary arterial hypertension","volume":"22","author":"Humbert","year":"2003","journal-title":"Eur. Respir. J."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.jvir.2010.02.030","article-title":"Hypoxia-induced phenotypic switch of fibroblasts to myofibroblasts through a matrix metalloproteinase 2\/tissue inhibitor of metalloproteinase-mediated pathway: Implications for venous neointimal hyperplasia in hemodialysis access","volume":"21","author":"Misra","year":"2010","journal-title":"J. Vasc. Interv. Radiol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jacc.2004.02.029","article-title":"Cellular and molecular pathobiology of pulmonary arterial hypertension","volume":"43","author":"Humbert","year":"2004","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1161\/CIRCULATIONAHA.105.609008","article-title":"An abnormal mitochondrial-hypoxia inducible factor-1alpha-Kv channel pathway disrupts oxygen sensing and triggers pulmonary arterial hypertension in fawn hooded rats: Similarities to human pulmonary arterial hypertension","volume":"113","author":"Bonnet","year":"2006","journal-title":"Circulation"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1164\/rccm.2106007","article-title":"CX(3)C chemokine fractalkine in pulmonary arterial hypertension","volume":"165","author":"Balabanian","year":"2002","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1056\/NEJMoa1503184","article-title":"Selexipag for the Treatment of Pulmonary Arterial Hypertension","volume":"373","author":"Sitbon","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1056\/NEJMoa020204","article-title":"Inhaled iloprost for severe pulmonary hypertension","volume":"347","author":"Olschewski","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/0163-7258(90)90060-F","article-title":"Cyclic AMP and mechanisms of vasodilation","volume":"47","author":"Murray","year":"1990","journal-title":"Pharmacol. Ther."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1056\/NEJMoa1209657","article-title":"Riociguat for the treatment of chronic thromboembolic pulmonary hypertension","volume":"369","author":"Ghofrani","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1056\/NEJMoa050010","article-title":"Sildenafil citrate therapy for pulmonary arterial hypertension","volume":"353","author":"Galie","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJMoa012212","article-title":"Bosentan therapy for pulmonary arterial hypertension","volume":"346","author":"Rubin","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1086\/303059","article-title":"Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene","volume":"67","author":"Deng","year":"2000","journal-title":"Am. J. Hum. Genet."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/79226","article-title":"Heterozygous germline mutations in BMPR2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension","volume":"26","author":"International","year":"2000","journal-title":"Nat. Genet."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1097\/HCO.0000000000000105","article-title":"Genetics of pulmonary hypertension","volume":"29","author":"Best","year":"2014","journal-title":"Curr Opin Cardiol"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1002\/humu.22904","article-title":"Pulmonary Arterial Hypertension: A Current Perspective on Established and Emerging Molecular Genetic Defects","volume":"36","author":"Machado","year":"2015","journal-title":"Hum. Mutat."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/humu.20285","article-title":"Mutations of the TGF-beta type II receptor BMPR2 in pulmonary arterial hypertension","volume":"27","author":"Machado","year":"2006","journal-title":"Hum. Mutat."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1164\/rccm.201205-0886OC","article-title":"Longitudinal analysis casts doubt on the presence of genetic anticipation in heritable pulmonary arterial hypertension","volume":"186","author":"Larkin","year":"2012","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.jacc.2009.04.018","article-title":"Cellular and molecular basis of pulmonary arterial hypertension","volume":"54","author":"Morrell","year":"2009","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1136\/jmg.40.12.865","article-title":"Molecular and functional analysis identifies ALK-1 as the predominant cause of pulmonary hypertension related to hereditary haemorrhagic telangiectasia","volume":"40","author":"Harrison","year":"2003","journal-title":"J. Med. Genet."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1136\/thx.2003.11890","article-title":"Endoglin germline mutation in a patient with hereditary haemorrhagic telangiectasia and dexfenfluramine associated pulmonary arterial hypertension","volume":"59","author":"Chaouat","year":"2004","journal-title":"Thorax"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1253\/circj.CJ-11-1281","article-title":"Missense mutations of the BMPR1B (ALK6) gene in childhood idiopathic pulmonary arterial hypertension","volume":"76","author":"Chida","year":"2012","journal-title":"Circ. J."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1002\/humu.21605","article-title":"Molecular genetic characterization of SMAD signaling molecules in pulmonary arterial hypertension","volume":"32","author":"Nasim","year":"2011","journal-title":"Hum. Mutat."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Wang, G., Fan, R., Ji, R., Zou, W., Penny, D.J., Varghese, N.P., and Fan, Y. (2016). Novel homozygous BMP9 nonsense mutation causes pulmonary arterial hypertension: A case report. BMC Pulm. Med., 16.","DOI":"10.1186\/s12890-016-0183-7"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1038\/s41467-018-03672-4","article-title":"Identification of rare sequence variation underlying heritable pulmonary arterial hypertension","volume":"9","author":"Graf","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1161\/CIRCGENETICS.111.961888","article-title":"Whole exome sequencing to identify a novel gene (caveolin-1) associated with human pulmonary arterial hypertension","volume":"5","author":"Austin","year":"2012","journal-title":"Circ. Cardiovasc. Genet."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1056\/NEJMoa1211097","article-title":"A novel channelopathy in pulmonary arterial hypertension","volume":"369","author":"Ma","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1136\/jmedgenet-2012-101152","article-title":"TBX4 mutations (small patella syndrome) are associated with childhood-onset pulmonary arterial hypertension","volume":"50","author":"Bongers","year":"2013","journal-title":"J. Med. Genet."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.chest.2016.11.014","article-title":"EIF2AK4 Mutations in Patients Diagnosed With Pulmonary Arterial Hypertension","volume":"151","author":"Best","year":"2017","journal-title":"Chest"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"9484","DOI":"10.1073\/pnas.85.24.9484","article-title":"Purification and characterization of other distinct bone-inducing factors","volume":"85","author":"Wang","year":"1988","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1101\/gad.10.13.1580","article-title":"Bone morphogenetic proteins: Multifunctional regulators of vertebrate development","volume":"10","author":"Hogan","year":"1996","journal-title":"Genes Dev."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1002\/(SICI)1097-0177(200006)218:2<383::AID-DVDY11>3.0.CO;2-P","article-title":"Requirement for BMP and FGF signaling during cardiogenic induction in non-precardiac mesoderm is specific, transient, and cooperative","volume":"218","author":"Barron","year":"2000","journal-title":"Dev. Dyn."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S0092-8674(03)00432-X","article-title":"Mechanisms of TGF-beta signaling from cell membrane to the nucleus","volume":"113","author":"Shi","year":"2003","journal-title":"Cell"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cytogfr.2003.10.004","article-title":"The transforming growth factor-beta superfamily of receptors","volume":"15","year":"2004","journal-title":"Cytokine Growth Factor Rev."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1093\/jb\/mvp148","article-title":"Bone morphogenetic protein receptors and signal transduction","volume":"147","author":"Miyazono","year":"2010","journal-title":"J. Biochem."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"24443","DOI":"10.1074\/jbc.M502825200","article-title":"Bone morphogenetic protein (BMP) type II receptor deletion reveals BMP ligand-specific gain of signaling in pulmonary artery smooth muscle cells","volume":"280","author":"Yu","year":"2005","journal-title":"J. Biol. Chem."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1083\/jcb.200212060","article-title":"Direct signaling by the BMP type II receptor via the cytoskeletal regulator LIMK1","volume":"162","author":"Foletta","year":"2003","journal-title":"J. Cell Biol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"3277","DOI":"10.1093\/hmg\/ddg365","article-title":"Functional interaction between BMPR-II and Tctex-1, a light chain of Dynein, is isoform-specific and disrupted by mutations underlying primary pulmonary hypertension","volume":"12","author":"Machado","year":"2003","journal-title":"Hum. Mol. Genet."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"5776","DOI":"10.1128\/MCB.00218-07","article-title":"A novel regulatory mechanism of the bone morphogenetic protein (BMP) signaling pathway involving the carboxyl-terminal tail domain of BMP type II receptor","volume":"27","author":"Chan","year":"2007","journal-title":"Mol. Cell Biol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1152\/ajplung.00054.2013","article-title":"Id proteins are critical downstream effectors of BMP signaling in human pulmonary arterial smooth muscle cells","volume":"305","author":"Yang","year":"2013","journal-title":"Am. J. Physiol. Lung Cell Mol. Physiol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.cytogfr.2009.10.011","article-title":"Control of BMP gene expression by long-range regulatory elements","volume":"20","author":"Pregizer","year":"2009","journal-title":"Cytokine Growth Factor Rev."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1161\/CIRCULATIONAHA.112.106245","article-title":"Role of BMPR2 alternative splicing in heritable pulmonary arterial hypertension penetrance","volume":"126","author":"Cogan","year":"2012","journal-title":"Circulation"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1126\/science.8140412","article-title":"Characterization of type I receptors for transforming growth factor-beta and activin","volume":"264","author":"Yamashita","year":"1994","journal-title":"Science"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"25628","DOI":"10.1074\/jbc.273.40.25628","article-title":"Specific activation of Smad1 signaling pathways by the BMP7 type I receptor, ALK2","volume":"273","author":"Hoodless","year":"1998","journal-title":"J. Biol. Chem."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1083\/jcb.130.1.217","article-title":"Osteogenic protein-1 binds to activin type II receptors and induces certain activin-like effects","volume":"130","author":"Yamashita","year":"1995","journal-title":"J. Cell Biol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"3519","DOI":"10.1242\/jcs.112.20.3519","article-title":"Characterization of bone morphogenetic protein-6 signaling pathways in osteoblast differentiation","volume":"112","author":"Ebisawa","year":"1999","journal-title":"J. Cell Sci."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"25111","DOI":"10.1074\/jbc.M503328200","article-title":"Crystal structure of BMP-9 and functional interactions with pro-region and receptors","volume":"280","author":"Brown","year":"2005","journal-title":"J. Biol. Chem."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1182\/blood-2006-07-034124","article-title":"Identification of BMP9 and BMP10 as functional activators of the orphan activin receptor-like kinase 1 (ALK1) in endothelial cells","volume":"109","author":"David","year":"2007","journal-title":"Blood"},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Alt, A., Miguel-Romero, L., Donderis, J., Aristorena, M., Blanco, F.J., Round, A., Rubio, V., Bernabeu, C., and Marina, A. (2012). Structural and functional insights into endoglin ligand recognition and binding. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0029948"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"2783","DOI":"10.1101\/gad.1350705","article-title":"Smad transcription factors","volume":"19","author":"Massague","year":"2005","journal-title":"Genes Dev."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"a021899","DOI":"10.1101\/cshperspect.a021899","article-title":"Bone Morphogenetic Proteins","volume":"8","author":"Katagiri","year":"2016","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/S1097-2765(03)00386-1","article-title":"Activin receptor-like kinase (ALK)1 is an antagonistic mediator of lateral TGFbeta\/ALK5 signaling","volume":"12","author":"Goumans","year":"2003","journal-title":"Mol. Cell"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"6889","DOI":"10.1128\/MCB.01192-08","article-title":"Transforming growth factor beta-induced Smad1\/5 phosphorylation in epithelial cells is mediated by novel receptor complexes and is essential for anchorage-independent growth","volume":"28","author":"Daly","year":"2008","journal-title":"Mol. Cell Biol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/cr.2008.302","article-title":"Signaling cross-talk between TGF-beta\/BMP and other pathways","volume":"19","author":"Guo","year":"2009","journal-title":"Cell Res."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1046\/j.1365-2443.1999.00250.x","article-title":"Developmental patterning in chondrocytic cultures by morphogenic gradients: BMP induces expression of indian hedgehog and noggin","volume":"4","author":"Kameda","year":"1999","journal-title":"Genes Cells"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"4558","DOI":"10.1210\/endo.141.12.7851","article-title":"Bone morphogenetic proteins induce gremlin, a protein that limits their activity in osteoblasts","volume":"141","author":"Pereira","year":"2000","journal-title":"Endocrinology"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/S0092-8674(00)80425-0","article-title":"Production of a DPP activity gradient in the early Drosophila embryo through the opposing actions of the SOG and TLD proteins","volume":"91","author":"Marques","year":"1997","journal-title":"Cell"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/S0092-8674(00)80424-9","article-title":"Cleavage of Chordin by Xolloid metalloprotease suggests a role for proteolytic processing in the regulation of Spemann organizer activity","volume":"91","author":"Piccolo","year":"1997","journal-title":"Cell"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"5664","DOI":"10.1128\/MCB.23.16.5664-5679.2003","article-title":"BMPER, a novel endothelial cell precursor-derived protein, antagonizes bone morphogenetic protein signaling and endothelial cell differentiation","volume":"23","author":"Moser","year":"2003","journal-title":"Mol. Cell. Biol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1750-2187-2-4","article-title":"Role of RGM coreceptors in bone morphogenetic protein signaling","volume":"2","author":"Halbrooks","year":"2007","journal-title":"J. Mol. Signal"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1038\/39355","article-title":"Smad6 inhibits signalling by the TGF-beta superfamily","volume":"389","author":"Imamura","year":"1997","journal-title":"Nature"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s00441-011-1190-x","article-title":"Role of Smads in TGFbeta signaling","volume":"347","author":"Heldin","year":"2012","journal-title":"Cell Tissue Res."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1038\/23293","article-title":"A SMAD ubiquitin ligase targets the BMP pathway and affects embryonic pattern formation","volume":"400","author":"Zhu","year":"1999","journal-title":"Nature"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"2809","DOI":"10.1091\/mbc.e02-07-0441","article-title":"Cooperative inhibition of bone morphogenetic protein signaling by Smurf1 and inhibitory Smads","volume":"14","author":"Murakami","year":"2003","journal-title":"Mol. Biol. Cell"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"3399","DOI":"10.1242\/jcs.086710","article-title":"MicroRNA-21 is an important downstream component of BMP signalling in epidermal keratinocytes","volume":"124","author":"Ahmed","year":"2011","journal-title":"J. Cell Sci."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"38656","DOI":"10.1074\/jbc.M112.390898","article-title":"Inhibition of microRNA-302 (miR-302) by bone morphogenetic protein 4 (BMP4) facilitates the BMP signaling pathway","volume":"287","author":"Kang","year":"2012","journal-title":"J. Biol. Chem."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"3600","DOI":"10.1172\/JCI65592","article-title":"FK506 activates BMPR2, rescues endothelial dysfunction, and reverses pulmonary hypertension","volume":"123","author":"Spiekerkoetter","year":"2013","journal-title":"J. Clin. Invest."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1152\/ajpcell.00057.2014","article-title":"Identification of a common Wnt-associated genetic signature across multiple cell types in pulmonary arterial hypertension","volume":"307","author":"West","year":"2014","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1164\/rccm.201606-1200OC","article-title":"Induced Pluripotent Stem Cell Model of Pulmonary Arterial Hypertension Reveals Novel Gene Expression and Patient Specificity","volume":"195","author":"Sa","year":"2017","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.stem.2016.08.019","article-title":"Patient-Specific iPSC-Derived Endothelial Cells Uncover Pathways that Protect against Pulmonary Hypertension in BMPR2 Mutation Carriers","volume":"20","author":"Gu","year":"2017","journal-title":"Cell Stem Cell"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1164\/rccm.201801-0049LE","article-title":"Contributions of BMPR2 Mutations and Extrinsic Factors to Cellular Phenotypes of Pulmonary Arterial Hypertension Revealed by Induced Pluripotent Stem Cell Modeling","volume":"198","author":"Kiskin","year":"2018","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1126\/science.282.5391.1145","article-title":"Embryonic stem cell lines derived from human blastocysts","volume":"282","author":"Thomson","year":"1998","journal-title":"Science"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"13726","DOI":"10.1073\/pnas.95.23.13726","article-title":"Derivation of pluripotent stem cells from cultured human primordial germ cells","volume":"95","author":"Shamblott","year":"1998","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1016\/j.cell.2013.05.006","article-title":"Human embryonic stem cells derived by somatic cell nuclear transfer","volume":"153","author":"Tachibana","year":"2013","journal-title":"Cell"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/nature13287","article-title":"Human oocytes reprogram adult somatic nuclei of a type 1 diabetic to diploid pluripotent stem cells","volume":"510","author":"Yamada","year":"2014","journal-title":"Nature"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.cell.2006.07.024","article-title":"Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors","volume":"126","author":"Takahashi","year":"2006","journal-title":"Cell"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.cell.2007.11.019","article-title":"Induction of pluripotent stem cells from adult human fibroblasts by defined factors","volume":"131","author":"Takahashi","year":"2007","journal-title":"Cell"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1126\/science.1151526","article-title":"Induced pluripotent stem cell lines derived from human somatic cells","volume":"318","author":"Yu","year":"2007","journal-title":"Science"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/nature06534","article-title":"Reprogramming of human somatic cells to pluripotency with defined factors","volume":"451","author":"Park","year":"2008","journal-title":"Nature"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nbt1374","article-title":"Generation of induced pluripotent stem cells without Myc from mouse and human fibroblasts","volume":"26","author":"Nakagawa","year":"2008","journal-title":"Nat. Biotechnol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.csbj.2014.11.003","article-title":"The role of purinergic receptors in stem cell differentiation","volume":"13","author":"Kaebisch","year":"2015","journal-title":"Comput Struct Biotechnol. J."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.stem.2007.07.019","article-title":"Teratoma formation assays with human embryonic stem cells: A rationale for one type of human-animal chimera","volume":"1","author":"Lensch","year":"2007","journal-title":"Cell Stem Cell"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1126\/science.1162494","article-title":"Induced pluripotent stem cells generated without viral integration","volume":"322","author":"Stadtfeld","year":"2008","journal-title":"Science"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1038\/nbt.1580","article-title":"Live cell imaging distinguishes bona fide human iPS cells from partially reprogrammed cells","volume":"27","author":"Chan","year":"2009","journal-title":"Nat. Biotechnol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/nature10761","article-title":"The promise of induced pluripotent stem cells in research and therapy","volume":"481","author":"Robinton","year":"2012","journal-title":"Nature"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.cell.2007.07.026","article-title":"TRIM28 mediates primer binding site-targeted silencing of murine leukemia virus in embryonic cells","volume":"131","author":"Wolf","year":"2007","journal-title":"Cell"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1126\/science.1158799","article-title":"Induced pluripotent stem cells generated from patients with ALS can be differentiated into motor neurons","volume":"321","author":"Dimos","year":"2008","journal-title":"Science"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/nature07677","article-title":"Induced pluripotent stem cells from a spinal muscular atrophy patient","volume":"457","author":"Ebert","year":"2009","journal-title":"Nature"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1016\/j.cell.2009.02.013","article-title":"Parkinson\u2019s disease patient-derived induced pluripotent stem cells free of viral reprogramming factors","volume":"136","author":"Soldner","year":"2009","journal-title":"Cell"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1634\/stemcells.2008-0922","article-title":"Hematopoietic and endothelial differentiation of human induced pluripotent stem cells","volume":"27","author":"Choi","year":"2009","journal-title":"Stem Cells"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"5473","DOI":"10.1182\/blood-2009-04-217406","article-title":"Human-induced pluripotent stem cells from blood cells of healthy donors and patients with acquired blood disorders","volume":"114","author":"Ye","year":"2009","journal-title":"Blood"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/j.febslet.2009.02.031","article-title":"Adipogenic differentiation of human induced pluripotent stem cells: Comparison with that of human embryonic stem cells","volume":"583","author":"Taura","year":"2009","journal-title":"FEBS Lett."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.stem.2008.08.014","article-title":"A drug-inducible system for direct reprogramming of human somatic cells to pluripotency","volume":"3","author":"Hockemeyer","year":"2008","journal-title":"Cell Stem Cell"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.stem.2008.08.003","article-title":"A high-efficiency system for the generation and study of human induced pluripotent stem cells","volume":"3","author":"Maherali","year":"2008","journal-title":"Cell Stem Cell"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1038\/ncb3205","article-title":"Generation of vascular endothelial and smooth muscle cells from human pluripotent stem cells","volume":"17","author":"Patsch","year":"2015","journal-title":"Nat. Cell Biol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/nbt.2107","article-title":"Generation of human vascular smooth muscle subtypes provides insight into embryological origin-dependent disease susceptibility","volume":"30","author":"Cheung","year":"2012","journal-title":"Nat. Biotechnol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/nrd.2016.245","article-title":"Induced pluripotent stem cell technology: A decade of progress","volume":"16","author":"Shi","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"ap482","DOI":"10.1161\/res.129.suppl_1.P482","article-title":"Elucidating and Characterizing the Molecular Mechanistic Role of Phospholamban L39 Stop in the Pathophysiology of Cardiomyopathy Using Patient-derived Human Induced Pluripotent Stem Cells and Humanized Knock-in Mouse Model Systems","volume":"129","author":"Devendran","year":"2021","journal-title":"Circ. Res."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.stem.2016.04.013","article-title":"Induced Pluripotent Stem Cells Meet Genome Editing","volume":"18","author":"Hockemeyer","year":"2016","journal-title":"Cell Stem Cell"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1038\/nbt.1562","article-title":"Efficient targeting of expressed and silent genes in human ESCs and iPSCs using zinc-finger nucleases","volume":"27","author":"Hockemeyer","year":"2009","journal-title":"Nat. Biotechnol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1038\/nprot.2011.431","article-title":"A transcription activator-like effector toolbox for genome engineering","volume":"7","author":"Sanjana","year":"2012","journal-title":"Nat. Protoc."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1126\/science.1247005","article-title":"Genome-scale CRISPR-Cas9 knockout screening in human cells","volume":"343","author":"Shalem","year":"2014","journal-title":"Science"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"10965","DOI":"10.1038\/ncomms10965","article-title":"The TLX-miR-219 cascade regulates neural stem cell proliferation in neurodevelopment and schizophrenia iPSC model","volume":"7","author":"Murai","year":"2016","journal-title":"Nat. Commun."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1007\/s00109-016-1426-z","article-title":"Identifying microRNAs targeting Wnt\/beta-catenin pathway in end-stage idiopathic pulmonary arterial hypertension","volume":"94","author":"Wu","year":"2016","journal-title":"J. Mol. Med."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1165\/rcmb.2008-0153OC","article-title":"The noncanonical WNT pathway is operative in idiopathic pulmonary arterial hypertension","volume":"40","author":"Laumanns","year":"2009","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.cmet.2015.03.010","article-title":"BMPR2 preserves mitochondrial function and DNA during reoxygenation to promote endothelial cell survival and reverse pulmonary hypertension","volume":"21","author":"Diebold","year":"2015","journal-title":"Cell Metab."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"102488","DOI":"10.1016\/j.scr.2021.102488","article-title":"Generation of pulmonary arterial hypertension patient-specific induced pluripotent stem cell lines from three unrelated patients with a heterozygous missense mutation in exon 12, a heterozygous in-frame deletion in exon 3 and a missense mutation in exon 11 of the BMPR2 gene","volume":"55","author":"Usman","year":"2021","journal-title":"Stem Cell Res."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1038\/nprot.2014.102","article-title":"Generation, expansion and functional analysis of endothelial cells and pericytes derived from human pluripotent stem cells","volume":"9","author":"Orlova","year":"2014","journal-title":"Nat. Protoc."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"e05098","DOI":"10.7554\/eLife.05098","article-title":"In vitro generation of human pluripotent stem cell derived lung organoids","volume":"4","author":"Dye","year":"2015","journal-title":"Elife"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"103797","DOI":"10.1016\/j.isci.2022.103797","article-title":"Metabolomic profiling of human pluripotent stem cell differentiation into lung progenitors","volume":"25","author":"Leibel","year":"2022","journal-title":"iScience"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"3334","DOI":"10.1039\/D0LC00605J","article-title":"Pulmonary-arterial-hypertension (PAH)-on-a-chip: Fabrication, validation and application","volume":"20","author":"Keshavarz","year":"2020","journal-title":"Lab Chip"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"L1025","DOI":"10.1152\/ajplung.00559.2020","article-title":"Newer insights into the pathobiological and pharmacological basis of the sex disparity in patients with pulmonary arterial hypertension","volume":"320","author":"Hye","year":"2021","journal-title":"Am. J. Physiol. Lung Cell Mol. Physiol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1038\/s41536-021-00183-7","article-title":"Induced pluripotency in the context of stem cell expansion bioprocess development, optimization, and manufacturing: A roadmap to the clinic","volume":"6","author":"Colter","year":"2021","journal-title":"NPJ Regen. Med."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1056\/NEJM199207093270203","article-title":"The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension","volume":"327","author":"Rich","year":"1992","journal-title":"N. Engl. J. Med."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1124\/pr.110.002907","article-title":"cGMP-dependent protein kinases and cGMP phosphodiesterases in nitric oxide and cGMP action","volume":"62","author":"Francis","year":"2010","journal-title":"Pharmacol. Rev."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1056\/NEJMoa1209655","article-title":"Riociguat for the treatment of pulmonary arterial hypertension","volume":"369","author":"Ghofrani","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1183\/09031936.00090614","article-title":"Riociguat for the treatment of pulmonary arterial hypertension: A long-term extension study (PATENT-2)","volume":"45","author":"Rubin","year":"2015","journal-title":"Eur. Respir. J."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1161\/01.CIR.0000029100.82385.58","article-title":"Survival in primary pulmonary hypertension: The impact of epoprostenol therapy","volume":"106","author":"McLaughlin","year":"2002","journal-title":"Circulation"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1213917","article-title":"Macitentan and morbidity and mortality in pulmonary arterial hypertension","volume":"369","author":"Pulido","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1152\/ajplung.00309.2006","article-title":"Overexpression of human bone morphogenetic protein receptor 2 does not ameliorate monocrotaline pulmonary arterial hypertension","volume":"292","author":"McMurtry","year":"2007","journal-title":"Am. J. Physiol. Lung Cell Mol. Physiol."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1152\/ajplung.00020.2006","article-title":"Bone morphogenetic protein type 2 receptor gene therapy attenuates hypoxic pulmonary hypertension","volume":"292","author":"Reynolds","year":"2007","journal-title":"Am. J. Physiol. Lung Cell Mol. Physiol."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1183\/09031936.00187310","article-title":"Targeted gene delivery of BMPR2 attenuates pulmonary hypertension","volume":"39","author":"Reynolds","year":"2012","journal-title":"Eur. Respir. J."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1111\/resp.12729","article-title":"BMPR2 gene therapy for PAH acts via Smad and non-Smad signalling","volume":"21","author":"Harper","year":"2016","journal-title":"Respirology"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1111\/resp.13552","article-title":"BMPR2-expressing bone marrow-derived endothelial-like progenitor cells alleviate pulmonary arterial hypertension in vivo","volume":"24","author":"Harper","year":"2019","journal-title":"Respirology"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1093\/cvr\/cvw054","article-title":"Exosomes induce and reverse monocrotaline-induced pulmonary hypertension in mice","volume":"110","author":"Aliotta","year":"2016","journal-title":"Cardiovasc. Res."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1101\/gad.1566807","article-title":"Quality control of eukaryotic mRNA: Safeguarding cells from abnormal mRNA function","volume":"21","author":"Isken","year":"2007","journal-title":"Genes Dev."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00439-013-1358-4","article-title":"The Human Gene Mutation Database: Building a comprehensive mutation repository for clinical and molecular genetics, diagnostic testing and personalized genomic medicine","volume":"133","author":"Stenson","year":"2014","journal-title":"Hum. Genet."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/S0968-0004(98)01208-0","article-title":"A rule for termination-codon position within intron-containing genes: When nonsense affects RNA abundance","volume":"23","author":"Nagy","year":"1998","journal-title":"Trends Biochem. Sci."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1038\/nature12531","article-title":"Transcriptome and genome sequencing uncovers functional variation in humans","volume":"501","author":"Lappalainen","year":"2013","journal-title":"Nature"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1164\/ajrccm.163.7.2004001","article-title":"Evidence that systemic gentamicin suppresses premature stop mutations in patients with cystic fibrosis","volume":"163","author":"Clancy","year":"2001","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1056\/NEJMoa022170","article-title":"Gentamicin-induced correction of CFTR function in patients with cystic fibrosis and CFTR stop mutations","volume":"349","author":"Wilschanski","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.tig.2008.08.010","article-title":"Introducing sense into nonsense in treatments of human genetic diseases","volume":"24","author":"Linde","year":"2008","journal-title":"Trends Genet."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1093\/embo-reports\/kve176","article-title":"Impact of the six nucleotides downstream of the stop codon on translation termination","volume":"2","author":"Namy","year":"2001","journal-title":"EMBO Rep."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1093\/hmg\/ddn059","article-title":"Stoichiometric imbalance in the receptor complex contributes to dysfunctional BMPR-II mediated signalling in pulmonary arterial hypertension","volume":"17","author":"Nasim","year":"2008","journal-title":"Hum. Mol. Genet."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/nature05756","article-title":"PTC124 targets genetic disorders caused by nonsense mutations","volume":"447","author":"Welch","year":"2007","journal-title":"Nature"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1183\/09031936.00120910","article-title":"Chronic ataluren (PTC124) treatment of nonsense mutation cystic fibrosis","volume":"38","author":"Wilschanski","year":"2011","journal-title":"Eur. Respir. J."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"P3.164","DOI":"10.1212\/WNL.86.16_supplement.P3.164","article-title":"Safety and Tolerability of Ataluren in a Phase 3 Study of Patients with Nonsense Mutation Duchenne Muscular Dystrophy (P3.164)","volume":"86","author":"Campbell","year":"2016","journal-title":"Neurology"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1165\/rcmb.2013-0100OC","article-title":"Correction of nonsense BMPR2 and SMAD9 mutations by ataluren in pulmonary arterial hypertension","volume":"49","author":"Drake","year":"2013","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/2045894020935783","article-title":"Targeting translational read-through of premature termination mutations in BMPR2 with PTC124 for pulmonary arterial hypertension","volume":"10","author":"Long","year":"2020","journal-title":"Pulm. Circ."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1124\/mol.110.067447","article-title":"Immunosuppressor FK506 increases endoglin and activin receptor-like kinase 1 expression and modulates transforming growth factor-beta1 signaling in endothelial cells","volume":"79","author":"Albinana","year":"2011","journal-title":"Mol. Pharmacol."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1164\/rccm.201411-2061LE","article-title":"Low-Dose FK506 (Tacrolimus) in End-Stage Pulmonary Arterial Hypertension","volume":"192","author":"Spiekerkoetter","year":"2015","journal-title":"Am. J. Respir. Crit Care Med."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"1602449","DOI":"10.1183\/13993003.02449-2016","article-title":"Randomised placebo-controlled safety and tolerability trial of FK506 (tacrolimus) for pulmonary arterial hypertension","volume":"50","author":"Spiekerkoetter","year":"2017","journal-title":"Eur. Respir. J."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1161\/CIRCULATIONAHA.108.821504","article-title":"Altered bone morphogenetic protein and transforming growth factor-beta signaling in rat models of pulmonary hypertension: Potential for activin receptor-like kinase-5 inhibition in prevention and progression of disease","volume":"119","author":"Long","year":"2009","journal-title":"Circulation"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1152\/japplphysiol.90719.2008","article-title":"Elevated levels of activin A in clinical and experimental pulmonary hypertension","volume":"106","author":"Yndestad","year":"2009","journal-title":"J. Appl. Physiol."},{"key":"ref_156","doi-asserted-by":"crossref","unstructured":"Kudryashova, T.V., Shen, Y., Pena, A., Cronin, E., Okorie, E., Goncharov, D.A., and Goncharova, E.A. (2018). Inhibitory Antibodies against Activin A and TGF-beta Reduce Self-Supported, but Not Soluble Factors-Induced Growth of Human Pulmonary Arterial Vascular Smooth Muscle Cells in Pulmonary Arterial Hypertension. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19102957"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"172679","DOI":"10.1016\/j.ejphar.2019.172679","article-title":"Monocrotaline pyrrole enhanced bone morphogenetic protein 7 signaling transduced by alternative activin A receptor type 2A in pulmonary arterial smooth muscle cells","volume":"863","author":"Sun","year":"2019","journal-title":"Eur. J. Pharmacol."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"14079","DOI":"10.1038\/ncomms14079","article-title":"TNFalpha drives pulmonary arterial hypertension by suppressing the BMP type-II receptor and altering NOTCH signalling","volume":"8","author":"Hurst","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"15794","DOI":"10.1074\/jbc.M109.002881","article-title":"Bone morphogenetic protein (BMP) and activin type II receptors balance BMP9 signals mediated by activin receptor-like kinase-1 in human pulmonary artery endothelial cells","volume":"284","author":"Upton","year":"2009","journal-title":"J. Biol. Chem."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"aaz5660","DOI":"10.1126\/scitranslmed.aaz5660","article-title":"ACTRIIA-Fc rebalances activin\/GDF versus BMP signaling in pulmonary hypertension","volume":"12","author":"Yung","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"477","DOI":"10.3324\/haematol.2018.198887","article-title":"Sotatercept, a novel transforming growth factor beta ligand trap, improves anemia in beta-thalassemia: A phase II, open-label, dose-finding study","volume":"104","author":"Cappellini","year":"2019","journal-title":"Haematologica"},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S2352-3026(18)30002-4","article-title":"Sotatercept with long-term extension for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes: A phase 2, dose-ranging trial","volume":"5","author":"Komrokji","year":"2018","journal-title":"Lancet Haematol"},{"key":"ref_163","first-page":"2201347","article-title":"Sotatercept for the treatment of pulmonary arterial hypertension: PULSAR open-label extension","volume":"60","author":"Humbert","year":"2022","journal-title":"Eur. Respir. J."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1056\/NEJMoa2024277","article-title":"Sotatercept for the Treatment of Pulmonary Arterial Hypertension","volume":"384","author":"Humbert","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_165","first-page":"275","article-title":"Exuberant endothelial cell growth and elements of inflammation are present in plexiform lesions of pulmonary hypertension","volume":"144","author":"Tuder","year":"1994","journal-title":"Am. J. Pathol."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.1161\/01.CIR.102.22.2720","article-title":"Increased plasma P-selectin and decreased thrombomodulin in pulmonary arterial hypertension were improved by continuous prostacyclin therapy","volume":"102","author":"Sakamaki","year":"2000","journal-title":"Circulation"},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1161\/CIRCULATIONAHA.109.933762","article-title":"Elevated levels of inflammatory cytokines predict survival in idiopathic and familial pulmonary arterial hypertension","volume":"122","author":"Soon","year":"2010","journal-title":"Circulation"},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1465-9921-10-6","article-title":"Impact of interleukin-6 on hypoxia-induced pulmonary hypertension and lung inflammation in mice","volume":"10","author":"Savale","year":"2009","journal-title":"Respir. Res."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1161\/CIRCRESAHA.108.182014","article-title":"Interleukin-6 overexpression induces pulmonary hypertension","volume":"104","author":"Steiner","year":"2009","journal-title":"Circ. Res."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1172\/JCI96462","article-title":"Ectopic upregulation of membrane-bound IL6R drives vascular remodeling in pulmonary arterial hypertension","volume":"128","author":"Tamura","year":"2018","journal-title":"J. Clin. Invest."},{"key":"ref_171","first-page":"1","article-title":"Clinical trial protocol for TRANSFORM-UK: A therapeutic open-label study of tocilizumab in the treatment of pulmonary arterial hypertension","volume":"8","author":"Harlow","year":"2018","journal-title":"Pulm. Circ."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"1901761","DOI":"10.1183\/13993003.01761-2019","article-title":"Cellular sources of interleukin-6 and associations with clinical phenotypes and outcomes in pulmonary arterial hypertension","volume":"55","author":"Simpson","year":"2020","journal-title":"Eur. Respir. J."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"2000314","DOI":"10.1183\/13993003.00314-2020","article-title":"IL-6 in pulmonary hypertension: Why novel is not always best","volume":"55","author":"Toshner","year":"2020","journal-title":"Eur. Respir. J."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1038\/ajg.2011.73","article-title":"Efficacy of biological therapies in inflammatory bowel disease: Systematic review and meta-analysis","volume":"106","author":"Ford","year":"2011","journal-title":"Am. J. Gastroenterol."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"478","DOI":"10.7326\/0003-4819-130-6-199903160-00004","article-title":"Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial","volume":"130","author":"Moreland","year":"1999","journal-title":"Ann. Intern. Med."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1136\/ard.61.4.298","article-title":"Tumour necrosis factor (TNF) in psoriatic arthritis: Pathophysiology and treatment with TNF inhibitors","volume":"61","author":"Mease","year":"2002","journal-title":"Ann. Rheum. Dis."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1161\/01.CIR.103.8.1044","article-title":"Results of targeted anti-tumor necrosis factor therapy with etanercept (ENBREL) in patients with advanced heart failure","volume":"103","author":"Bozkurt","year":"2001","journal-title":"Circulation"},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.5114\/aoms.2014.47827","article-title":"Tumor necrosis factor inhibitors\u2014State of knowledge","volume":"10","author":"Lis","year":"2014","journal-title":"Arch. Med. Sci."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/1756-185X.12304","article-title":"Preventive and remedial application of etanercept attenuate monocrotaline-induced pulmonary arterial hypertension","volume":"19","author":"Zhang","year":"2016","journal-title":"Int. J. Rheum. Dis."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1056\/NEJMoa035115","article-title":"Expression of human herpesvirus 8 in primary pulmonary hypertension","volume":"349","author":"Cool","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1086\/427824","article-title":"Lack of human herpesvirus 8 infection in lungs of Japanese patients with primary pulmonary hypertension","volume":"191","author":"Katano","year":"2005","journal-title":"J. Infect. Dis."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1164\/rccm.200504-546OC","article-title":"Absence of Kaposi\u2019s sarcoma-associated herpesvirus in patients with pulmonary arterial hypertension","volume":"172","author":"Mengel","year":"2005","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1172\/JCI12432","article-title":"A viral protein that selectively downregulates ICAM-1 and B7-2 and modulates T cell costimulation","volume":"107","author":"Coscoy","year":"2001","journal-title":"J. Clin. Invest."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1182\/blood-2005-11-4404","article-title":"Kaposi sarcoma herpesvirus K5 removes CD31\/PECAM from endothelial cells","volume":"108","author":"Mansouri","year":"2006","journal-title":"Blood"},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"37641","DOI":"10.1074\/jbc.M110.132415","article-title":"Identification of a lysosomal pathway regulating degradation of the bone morphogenetic protein receptor type II","volume":"285","author":"Durrington","year":"2010","journal-title":"J. Biol. Chem."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s12016-010-8243-x","article-title":"Hydroxychloroquine: From malaria to autoimmunity","volume":"42","author":"Kivity","year":"2012","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1161\/CIRCRESAHA.111.300483","article-title":"Chloroquine prevents progression of experimental pulmonary hypertension via inhibition of autophagy and lysosomal bone morphogenetic protein type II receptor degradation","volume":"112","author":"Long","year":"2013","journal-title":"Circ. Res."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"3667","DOI":"10.1093\/hmg\/ddt216","article-title":"The lysosomal inhibitor, chloroquine, increases cell surface BMPR-II levels and restores BMP9 signalling in endothelial cells harbouring BMPR-II mutations","volume":"22","author":"Dunmore","year":"2013","journal-title":"Hum. Mol. Genet."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1002\/path.5322","article-title":"Autophagy contributes to BMP type 2 receptor degradation and development of pulmonary arterial hypertension","volume":"249","author":"Huang","year":"2019","journal-title":"J. Pathol."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"2979","DOI":"10.1007\/s00018-017-2510-4","article-title":"BMP type II receptor as a therapeutic target in pulmonary arterial hypertension","volume":"74","author":"Orriols","year":"2017","journal-title":"Cell Mol. Life Sci."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"3180","DOI":"10.1093\/hmg\/ddn214","article-title":"Failure of bone morphogenetic protein receptor trafficking in pulmonary arterial hypertension: Potential for rescue","volume":"17","author":"Sobolewski","year":"2008","journal-title":"Hum. Mol. Genet."},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1038\/nm.3877","article-title":"Selective enhancement of endothelial BMPR-II with BMP9 reverses pulmonary arterial hypertension","volume":"21","author":"Long","year":"2015","journal-title":"Nat. Med."},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1089\/jir.2006.26.661","article-title":"Etanercept reduces late endotoxin-induced pulmonary hypertension in the pig","volume":"26","author":"Mutschler","year":"2006","journal-title":"J. Interferon. Cytokine Res."},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1111\/bjh.12835","article-title":"Sotatercept in patients with osteolytic lesions of multiple myeloma","volume":"165","author":"Abdulkadyrov","year":"2014","journal-title":"Br. J. Haematol."},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1161\/CIRCULATIONAHA.113.006167","article-title":"Role for DNA damage signaling in pulmonary arterial hypertension","volume":"129","author":"Meloche","year":"2014","journal-title":"Circulation"},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"2553","DOI":"10.2147\/CMAR.S169558","article-title":"The efficacy and safety of olaparib in the treatment of cancers: A meta-analysis of randomized controlled trials","volume":"10","author":"Guo","year":"2018","journal-title":"Cancer Manag. Res."},{"key":"ref_197","doi-asserted-by":"crossref","unstructured":"Frump, A.L., Lowery, J.W., Hamid, R., Austin, E.D., and de Caestecker, M. (2013). Abnormal trafficking of endogenously expressed BMPR2 mutant allelic products in patients with heritable pulmonary arterial hypertension. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0080319"},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1165\/rcmb.2019-0321OC","article-title":"4PBA Restores Signaling of a Cysteine-substituted Mutant BMPR2 Receptor Found in Patients with Pulmonary Arterial Hypertension","volume":"63","author":"Dunmore","year":"2020","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"H1314","DOI":"10.1152\/ajpheart.00869.2013","article-title":"Reduction of endoplasmic reticulum stress by 4-phenylbutyric acid prevents the development of hypoxia-induced pulmonary arterial hypertension","volume":"306","author":"Koyama","year":"2014","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1161\/CIRCULATIONAHA.112.133413","article-title":"Attenuating endoplasmic reticulum stress as a novel therapeutic strategy in pulmonary hypertension","volume":"127","author":"Dromparis","year":"2013","journal-title":"Circulation"},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1134\/S0026893317060048","article-title":"Conformational Fingerprinting Using Monoclonal Antibodies (on the Example of Angiotensin I-Converting Enzyme-ACE)","volume":"51","author":"Danilov","year":"2017","journal-title":"Mol. Biol."}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/11\/23\/3823\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:28:56Z","timestamp":1760146136000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/11\/23\/3823"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,29]]},"references-count":201,"journal-issue":{"issue":"23","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["cells11233823"],"URL":"https:\/\/doi.org\/10.3390\/cells11233823","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,29]]}}}